+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
RNA Therapy Market by Therapeutic Area, Modality, Delivery System, Stage of Development, End User, Distribution Channel - Global Forecast to 2030- Product Image
RNA Therapy Market by Therapeutic Area, Modality, Delivery System, Stage of Development, End User, Distribution Channel - Global Forecast to 2030- Product Image
Sale

RNA Therapy Market by Therapeutic Area, Modality, Delivery System, Stage of Development, End User, Distribution Channel - Global Forecast to 2030

  • PDF Icon

    Report

  • 184 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 4968964
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The RNA Therapy Market is undergoing rapid transformation, driving new opportunities for stakeholders across the biotechnology, pharmaceutical, and clinical research sectors. Senior leaders face complex choices as scientific progress, technology shifts, and regulatory landscapes redefine standards in precision medicine.

Market Snapshot: RNA Therapy Market Growth and Trends

Between 2024 and 2025, the RNA Therapy Market will expand from USD 2.60 billion to USD 3.23 billion, maintaining strong momentum through a projected CAGR of 22.96% to 2030, where revenues are anticipated to reach USD 9.01 billion. This reflects increasing adoption driven by the growing acceptance of RNA modalities, demand for precision therapies, ongoing innovation in delivery systems, and a maturing commercialization infrastructure. Early leadership is emerging among biotechnology and pharmaceutical entities, positioning RNA therapeutics as a crucial pillar of next-generation healthcare.

Scope & Segmentation: Comprehensive Market Coverage

  • Therapeutic Area: Cardiovascular diseases, genetic disorders, infectious diseases (bacterial and viral), metabolic disorders, neurological disorders, oncology (hematological malignancies and solid tumors), rare diseases (including Gaucher disease, neuromuscular disorders, and sickle cell disease).
  • Modality: Antisense oligonucleotides, miRNA, mRNA, shRNA, siRNA.
  • Delivery System: Exosomes, lipid nanoparticles, polymer carriers (dendrimers and polyethyleneimine), viral vectors (AAV, lentivirus).
  • Stage of Development: Preclinical, Clinical Phase I, Clinical Phase II, Clinical Phase III, commercialized.
  • End User: Biotechnology companies, hospitals and clinics, pharmaceutical companies, research institutes.
  • Distribution Channel: Direct tender, online pharmacies, retail pharmacies.
  • Geographic Coverage: Americas (United States—California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio; Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan).
  • Companies Profiled: Moderna, Inc., BioNTech SE, Sarepta Therapeutics, Inc., Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Inc., CureVac N.V., Arcturus Therapeutics Holdings, Inc., Silence Therapeutics plc, Dicerna Pharmaceuticals, Inc.

Key Takeaways for Senior Decision-Makers

  • RNA therapy development is advancing beyond mRNA to a broad set of modalities, including antisense oligonucleotides and siRNA, expanding potential indications and patient populations.
  • Delivery technology innovation is key, with lipid nanoparticles and exosomes delivering improved stability, targeted tissue distribution, and scalability.
  • Strategic alliances and multi-disciplinary partnerships now underpin successful translational pipelines, enhancing speed-to-market and de-risking R&D investment.
  • Regional distinctions shape market dynamics: the Americas lead in early-stage innovation and manufacturing capacity, while Asia-Pacific’s rapid adoption supports continued pipeline growth and commercialization.
  • RNA therapy adoption in rare and ultra-rare diseases is accelerated by regulatory incentives and streamlined approval pathways, opening avenues for revenue diversification.

Tariff Impact on the RNA Therapy Market

Recent tariff policies in the United States have increased the costs of critical raw materials and reagents needed for oligonucleotide manufacturing. To control rising expenses and volatility, companies are adopting alternative sourcing, developing regional manufacturing hubs, and establishing nearshoring arrangements. Financial risk-sharing through partnerships is common, and many organizations are investing internally to heighten supply chain control. These measures are helping firms safeguard margins and ensure continuous progression along clinical and commercial pipelines.

Methodology & Data Sources

This report applies a robust methodology combining primary interviews with industry leaders and regulatory stakeholders and secondary research sourced from peer-reviewed publications, patents, company filings, and government documentation. The analysis leverages both bottom-up and top-down approaches, with data triangulation and stakeholder validation to produce accurate, actionable intelligence.

Why This Report Matters

  • Equips C-suite executives and strategy leaders with targeted insights into competitive dynamics, regulatory shifts, and technology adoption in the RNA therapy market.
  • Enables organizations to benchmark operational and sourcing strategies by understanding market segmentation, regional opportunities, and barriers to entry.
  • Supports evidence-based decision-making for portfolio management, risk mitigation, and investment allocation amid evolving global trade and supply chain realities.

Conclusion

The RNA Therapy Market report offers an essential reference for decision-makers navigating an increasingly complex and fast-moving landscape. Leverage these findings to inform strategic initiatives, enhance resilience, and position for sustainable growth in advanced therapeutics.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. RNA Therapy Market, by Therapeutic Area
8.1. Introduction
8.2. Cardiovascular Diseases
8.3. Genetic Disorders
8.4. Infectious Diseases
8.4.1. Bacterial Infections
8.4.2. Viral Infections
8.5. Metabolic Disorders
8.6. Neurological Disorders
8.7. Oncology
8.7.1. Hematological Malignancies
8.7.2. Solid Tumors
8.8. Rare Diseases
8.8.1. Gaucher Disease
8.8.2. Neuromuscular Disorders
8.8.3. Sickle Cell Disease
9. RNA Therapy Market, by Modality
9.1. Introduction
9.2. Antisense Oligonucleotide
9.3. MiRNA
9.4. mRNA
9.5. ShRNA
9.6. siRNA
10. RNA Therapy Market, by Delivery System
10.1. Introduction
10.2. Exosomes
10.3. Lipid Nanoparticles
10.4. Polymer Carriers
10.4.1. Dendrimers
10.4.2. Polyethyleneimine
10.5. Viral Vectors
10.5.1. AAV
10.5.2. Lentivirus
11. RNA Therapy Market, by Stage of Development
11.1. Introduction
11.2. Clinical Phase I
11.3. Clinical Phase II
11.4. Clinical Phase III
11.5. Commercialized
11.6. Preclinical
12. RNA Therapy Market, by End User
12.1. Introduction
12.2. Biotechnology Companies
12.3. Hospitals & Clinics
12.4. Pharmaceutical Companies
12.5. Research Institutes
13. RNA Therapy Market, by Distribution Channel
13.1. Introduction
13.2. Direct Tender
13.3. Online Pharmacies
13.4. Retail Pharmacies
14. Americas RNA Therapy Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa RNA Therapy Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific RNA Therapy Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Moderna, Inc.
17.3.2. BioNTech SE
17.3.3. Sarepta Therapeutics, Inc.
17.3.4. Alnylam Pharmaceuticals, Inc.
17.3.5. Ionis Pharmaceuticals, Inc.
17.3.6. Arrowhead Pharmaceuticals, Inc.
17.3.7. CureVac N.V.
17.3.8. Arcturus Therapeutics Holdings, Inc.
17.3.9. Silence Therapeutics plc
17.3.10. Dicerna Pharmaceuticals, Inc.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. RNA THERAPY MARKET MULTI-CURRENCY
FIGURE 2. RNA THERAPY MARKET MULTI-LANGUAGE
FIGURE 3. RNA THERAPY MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL RNA THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL RNA THERAPY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL RNA THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2030 (%)
FIGURE 8. GLOBAL RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL RNA THERAPY MARKET SIZE, BY MODALITY, 2024 VS 2030 (%)
FIGURE 10. GLOBAL RNA THERAPY MARKET SIZE, BY MODALITY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2024 VS 2030 (%)
FIGURE 12. GLOBAL RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL RNA THERAPY MARKET SIZE, BY STAGE OF DEVELOPMENT, 2024 VS 2030 (%)
FIGURE 14. GLOBAL RNA THERAPY MARKET SIZE, BY STAGE OF DEVELOPMENT, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL RNA THERAPY MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL RNA THERAPY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL RNA THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 18. GLOBAL RNA THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS RNA THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS RNA THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES RNA THERAPY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES RNA THERAPY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. RNA THERAPY MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. RNA THERAPY MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. RNA THERAPY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL RNA THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL RNA THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL RNA THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL RNA THERAPY MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL RNA THERAPY MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL RNA THERAPY MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL RNA THERAPY MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL RNA THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL RNA THERAPY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL RNA THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL RNA THERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL RNA THERAPY MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL RNA THERAPY MARKET SIZE, BY GAUCHER DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL RNA THERAPY MARKET SIZE, BY NEUROMUSCULAR DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL RNA THERAPY MARKET SIZE, BY SICKLE CELL DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL RNA THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL RNA THERAPY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL RNA THERAPY MARKET SIZE, BY MIRNA, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL RNA THERAPY MARKET SIZE, BY MRNA, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL RNA THERAPY MARKET SIZE, BY SHRNA, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL RNA THERAPY MARKET SIZE, BY SIRNA, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL RNA THERAPY MARKET SIZE, BY EXOSOMES, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL RNA THERAPY MARKET SIZE, BY LIPID NANOPARTICLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL RNA THERAPY MARKET SIZE, BY POLYMER CARRIERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL RNA THERAPY MARKET SIZE, BY DENDRIMERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL RNA THERAPY MARKET SIZE, BY POLYETHYLENEIMINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL RNA THERAPY MARKET SIZE, BY POLYMER CARRIERS, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL RNA THERAPY MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL RNA THERAPY MARKET SIZE, BY AAV, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL RNA THERAPY MARKET SIZE, BY LENTIVIRUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL RNA THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL RNA THERAPY MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL RNA THERAPY MARKET SIZE, BY CLINICAL PHASE I, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL RNA THERAPY MARKET SIZE, BY CLINICAL PHASE II, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL RNA THERAPY MARKET SIZE, BY CLINICAL PHASE III, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL RNA THERAPY MARKET SIZE, BY COMMERCIALIZED, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL RNA THERAPY MARKET SIZE, BY PRECLINICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL RNA THERAPY MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL RNA THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL RNA THERAPY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL RNA THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL RNA THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL RNA THERAPY MARKET SIZE, BY DIRECT TENDER, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL RNA THERAPY MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL RNA THERAPY MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS RNA THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS RNA THERAPY MARKET SIZE, BY POLYMER CARRIERS, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS RNA THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS RNA THERAPY MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS RNA THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES RNA THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES RNA THERAPY MARKET SIZE, BY POLYMER CARRIERS, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES RNA THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES RNA THERAPY MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES RNA THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES RNA THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 80. CANADA RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 81. CANADA RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 82. CANADA RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 83. CANADA RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 84. CANADA RNA THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 85. CANADA RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2030 (USD MILLION)
TABLE 86. CANADA RNA THERAPY MARKET SIZE, BY POLYMER CARRIERS, 2018-2030 (USD MILLION)
TABLE 87. CANADA RNA THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
TABLE 88. CANADA RNA THERAPY MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 89. CANADA RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 90. CANADA RNA THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 91. MEXICO RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 92. MEXICO RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 93. MEXICO RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 94. MEXICO RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 95. MEXICO RNA THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 96. MEXICO RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2030 (USD MILLION)
TABLE 97. MEXICO RNA THERAPY MARKET SIZE, BY POLYMER CARRIERS, 2018-2030 (USD MILLION)
TABLE 98. MEXICO RNA THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
TABLE 99. MEXICO RNA THERAPY MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 100. MEXICO RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 101. MEXICO RNA THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 102. BRAZIL RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 103. BRAZIL RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 104. BRAZIL RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 105. BRAZIL RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 106. BRAZIL RNA THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 107. BRAZIL RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2030 (USD MILLION)
TABLE 108. BRAZIL RNA THERAPY MARKET SIZE, BY POLYMER CARRIERS, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL RNA THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL RNA THERAPY MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL RNA THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 113. ARGENTINA RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 114. ARGENTINA RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 115. ARGENTINA RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 116. ARGENTINA RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 117. ARGENTINA RNA THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 118. ARGENTINA RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2030 (USD MILLION)
TABLE 119. ARGENTINA RNA THERAPY MARKET SIZE, BY POLYMER CARRIERS, 2018-2030 (USD MILLION)
TABLE 120. ARGENTINA RNA THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
TABLE 121. ARGENTINA RNA THERAPY MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 122. ARGENTINA RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 123. ARGENTINA RNA THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2030 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY POLYMER CARRIERS, 2018-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 136. UNITED KINGDOM RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 137. UNITED KINGDOM RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 138. UNITED KINGDOM RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 139. UNITED KINGDOM RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 140. UNITED KINGDOM RNA THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 141. UNITED KINGDOM RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2030 (USD MILLION)
TABLE 142. UNITED KINGDOM RNA THERAPY MARKET SIZE, BY POLYMER CARRIERS, 2018-2030 (USD MILLION)
TABLE 143. UNITED KINGDOM RNA THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
TABLE 144. UNITED KINGDOM RNA THERAPY MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 145. UNITED KINGDOM RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 146. UNITED KINGDOM RNA THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 147. GERMANY RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 148. GERMANY RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 149. GERMANY RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 150. GERMANY RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 151. GERMANY RNA THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 152. GERMANY RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2030 (USD MILLION)
TABLE 153. GERMANY RNA THERAPY MARKET SIZE, BY POLYMER CARRIERS, 2018-2030 (USD MILLION)
TABLE 154. GERMANY RNA THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
TABLE 155. GERMANY RNA THERAPY MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 156. GERMANY RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 157. GERMANY RNA THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 158. FRANCE RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 159. FRANCE RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 160. FRANCE RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 161. FRANCE RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 162. FRANCE RNA THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 163. FRANCE RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2030 (USD MILLION)
TABLE 164. FRANCE RNA THERAPY MARKET SIZE, BY POLYMER CARRIERS, 2018-2030 (USD MILLION)
TABLE 165. FRANCE RNA THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
TABLE 166. FRANCE RNA THERAPY MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 167. FRANCE RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 168. FRANCE RNA THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 169. RUSSIA RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 170. RUSSIA RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 171. RUSSIA RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 172. RUSSIA RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 173. RUSSIA RNA THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 174. RUSSIA RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2030 (USD MILLION)
TABLE 175. RUSSIA RNA THERAPY MARKET SIZE, BY POLYMER CARRIERS, 2018-2030 (USD MILLION)
TABLE 176. RUSSIA RNA THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
TABLE 177. RUSSIA RNA THERAPY MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 178. RUSSIA RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 179. RUSSIA RNA THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 180. ITALY RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 181. ITALY RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 182. ITALY RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 183. ITALY RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 184. ITALY RNA THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 185. ITALY RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2030 (USD MILLION)
TABLE 186. ITALY RNA THERAPY MARKET SIZE, BY POLYMER CARRIERS, 2018-2030 (USD MILLION)
TABLE 187. ITALY RNA THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
TABLE 188. ITALY RNA THERAPY MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 189. ITALY RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 190. ITALY RNA THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 191. SPAIN RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 192. SPAIN RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 193. SPAIN RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 194. SPAIN RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 195. SPAIN RNA THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 196. SPAIN RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2030 (USD MILLION)
TABLE 197. SPAIN RNA THERAPY MARKET SIZE, BY POLYMER CARRIERS, 2018-2030 (USD MILLION)
TABLE 198. SPAIN RNA THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
TABLE 199. SPAIN RNA THERAPY MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 200. SPAIN RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 201. SPAIN RNA THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 202. UNITED ARAB EMIRATES RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 203. UNITED ARAB EMIRATES RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 204. UNITED ARAB EMIRATES RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 205. UNITED ARAB EMIRATES RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 206. UNITED ARAB EMIRATES RNA THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 207. UNITED ARAB EMIRATES RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2030 (USD MILLION)
TABLE 208. UNITED ARAB EMIRATES RNA THERAPY MARKET SIZE, BY POLYMER CARRIERS, 2018-2030 (USD MILLION)
TABLE 209. UNITED ARAB EMIRATES RNA THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
TABLE 210. UNITED ARAB EMIRATES RNA THERAPY MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 211. UNITED ARAB EMIRATES RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 212. UNITED ARAB EMIRATES RNA THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 213. SAUDI ARABIA RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 214. SAUDI ARABIA RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 215. SAUDI ARABIA RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 216. SAUDI ARABIA RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 217. SAUDI ARABIA RNA THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 218. SAUDI ARABIA RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2030 (USD MILLION)
TABLE 219. SAUDI ARABIA RNA THERAPY MARKET SIZE, BY POLYMER CARRIERS, 2018-2030 (USD MILLION)
TABLE 220. SAUDI ARABIA RNA THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
TABLE 221. SAUDI ARABIA RNA THERAPY MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 222. SAUDI ARABIA RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 223. SAUDI ARABIA RNA THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 224. SOUTH AFRICA RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 225. SOUTH AFRICA RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 226. SOUTH AFRICA RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 227. SOUTH AFRICA RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 228. SOUTH AFRICA RNA THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 229. SOUTH AFRICA RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2030 (USD MILLION)
TABLE 230. SOUTH AFRICA RNA THERAPY MARKET SIZE, BY POLYMER CARRIERS, 2018-2030 (USD MILLION)
TABLE 231. SOUTH AFRICA RNA THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
TABLE 232. SOUTH AFRICA RNA THERAPY MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 233. SOUTH AFRICA RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 234. SOUTH AFRICA RNA THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 235. DENMARK RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 236. DENMARK RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 237. DENMARK RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 238. DENMARK RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 239. DENMARK RNA THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 240. DENMARK RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2030 (USD MILLION)
TABLE 241. DENMARK RNA THERAPY MARKET SIZE, BY POLYMER CARRIERS, 2018-2030 (USD MILLION)
TABLE 242. DENMARK RNA THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
TABLE 243. DENMARK RNA THERAPY MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 244. DENMARK RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 245. DENMARK RNA THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 246. NETHERLANDS RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 247. NETHERLANDS RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 248. NETHERLANDS RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 249. NETHERLANDS RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 250. NETHERLANDS RNA THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 251. NETHERLANDS RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2030 (USD MILLION)
TABLE 252. NETHERLANDS RNA THERAPY MARKET SIZE, BY POLYMER CARRIERS, 2018-2030 (USD MILLION)
TABLE 253. NETHERLANDS RNA THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
TABLE 254. NETHERLANDS RNA THERAPY MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 255. NETHERLANDS RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 256. NETHERLANDS RNA THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 257. QATAR RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 258. QATAR RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 259. QATAR RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 260. QATAR RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 261. QATAR RNA THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 262. QATAR RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2030 (USD MILLION)
TABLE 263. QATAR RNA THERAPY MARKET SIZE, BY POLYMER CARRIERS, 2018-2030 (USD MILLION)
TABLE 264. QATAR RNA THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
TABLE 265. QATAR RNA THERAPY MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 266. QATAR RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 267. QATAR RNA THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 268. FINLAND RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 269. FINLAND RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 270. FINLAND RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 271. FINLAND RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 272. FINLAND RNA THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 273. FINLAND RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2030 (USD MILLION)
TABLE 274. FINLAND RNA THERAPY MARKET SIZE, BY POLYMER CARRIERS, 2018-2030 (USD MILLION)
TABLE 275. FINLAND RNA THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
TABLE 276. FINLAND RNA THERAPY MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 277. FINLAND RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 278. FINLAND RNA THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 279. SWEDEN RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 280. SWEDEN RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 281. SWEDEN RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 282. SWEDEN RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 283. SWEDEN RNA THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 284. SWEDEN RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2030 (USD MILLION)
TABLE 285. SWEDEN RNA THERAPY MARKET SIZE, BY POLYMER CARRIERS, 2018-2030 (USD MILLION)
TABLE 286. SWEDEN RNA THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
TABLE 287. SWEDEN RNA THERAPY MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 288. SWEDEN RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 289. SWEDEN RNA THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 290. NIGERIA RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 291. NIGERIA RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 292. NIGERIA RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 293. NIGERIA RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 294. NIGERIA RNA THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 295. NIGERIA RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2030 (USD MILLION)
TABLE 296. NIGERIA RNA THERAPY MARKET SIZE, BY POLYMER CARRIERS, 2018-2030 (USD MILLION)
TABLE 297. NIGERIA RNA THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
TABLE 298. NIGERIA RNA THERAPY MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 299. NIGERIA RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 300. NIGERIA RNA THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 301. EGYPT RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 302. EGYPT RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 303. EGYPT RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 304. EGYPT RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 305. EGYPT RNA THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 306. EGYPT RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2030 (USD MILLION)
TABLE 307. EGYPT RNA THERAPY MARKET SIZE, BY POLYMER CARRIERS, 2018-2030 (USD MILLION)
TABLE 308. EGYPT RNA THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
TABLE 309. EGYPT RNA THERAPY MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 310. EGYPT RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 311. EGYPT RNA THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 312. TURKEY RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 313. TURKEY RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 314. TURKEY RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 315. TURKEY RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 316. TURKEY RNA THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 317. TURKEY RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2030 (USD MILLION)
TABLE 318. TURKEY RNA THERAPY MARKET SIZE, BY POLYMER CARRIERS, 2018-2030 (USD MILLION)
TABLE 319. TURKEY RNA THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
TABLE 320. TURKEY RNA THERAPY MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 321. TURKEY RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 322. TURKEY RNA THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 323. ISRAEL RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 324. ISRAEL RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 325. ISRAEL RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 326. ISRAEL RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 327. ISRAEL RNA THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 328. ISRAEL RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2030 (USD MILLION)
TABLE 329. ISRAEL RNA THERAPY MARKET SIZE, BY POLYMER CARRIERS, 2018-2030 (USD MILLION)
TABLE 330. ISRAEL RNA THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
TABLE 331. ISRAEL RNA THERAPY MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 332. ISRAEL RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 333. ISRAEL RNA THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 334. NORWAY RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 335. NORWAY RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 336. NORWAY RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 337. NORWAY RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 338. NORWAY RNA THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 339. NORWAY RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2030 (USD MILLION)
TABLE 340. NORWAY RNA THERAPY MARKET SIZE, BY POLYMER CARRIERS, 2018-2030 (USD MILLION)
TABLE 341. NORWAY RNA THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
TABLE 342. NORWAY RNA THERAPY MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 343. NORWAY RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 344. NORWAY RNA THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 345. POLAND RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 346. POLAND RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 347. POLAND RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 348. POLAND RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 349. POLAND RNA THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 350. POLAND RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2030 (USD MILLION)
TABLE 351. POLAND RNA THERAPY MARKET SIZE, BY POLYMER CARRIERS, 2018-2030 (USD MILLION)
TABLE 352. POLAND RNA THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
TABLE 353. POLAND RNA THERAPY MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 354. POLAND RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 355. POLAND RNA THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 356. SWITZERLAND RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 357. SWITZERLAND RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 358. SWITZERLAND RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 359. SWITZERLAND RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 360. SWITZERLAND RNA THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 361. SWITZERLAND RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2030 (USD MILLION)
TABLE 362. SWITZERLAND RNA THERAPY MARKET SIZE, BY POLYMER CARRIERS, 2018-2030 (USD MILLION)
TABLE 363. SWITZERLAND RNA THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
TABLE 364. SWITZERLAND RNA THERAPY MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 365. SWITZERLAND RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 366. SWITZERLAND RNA THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 367. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this RNA Therapy market report include:
  • Moderna, Inc.
  • BioNTech SE
  • Sarepta Therapeutics, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Ionis Pharmaceuticals, Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • CureVac N.V.
  • Arcturus Therapeutics Holdings, Inc.
  • Silence Therapeutics plc
  • Dicerna Pharmaceuticals, Inc.

Table Information

Report AttributeDetails
No. of Pages184
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 3.23 Billion
Forecasted Market Value ( USD ) by 2030 $ 9.01 Billion
Compound Annual Growth Rate22.9%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

RNA Interference Technology Market by Molecule Type, Route Of Administration, Delivery Method, Application, End-User - Global Forecast to 2030 - Product Image

RNA Interference Technology Market by Molecule Type, Route Of Administration, Delivery Method, Application, End-User - Global Forecast to 2030

  • Report
  • 183 Pages
  • Global
From
CircRNA Synthesis Market Size, Share & Trends Analysis Report By Product & Service (Reagents & Kits), By Application (Therapeutics Development), By End-use, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

CircRNA Synthesis Market Size, Share & Trends Analysis Report By Product & Service (Reagents & Kits), By Application (Therapeutics Development), By End-use, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 120 Pages
  • Global
From
SiRNA Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type - Product Image

SiRNA Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type

  • Report
  • 87 Pages
  • Global
From
RNA Therapy Clinical Trials - Global Strategic Business Report - Product Image

RNA Therapy Clinical Trials - Global Strategic Business Report

  • Report
  • 244 Pages
  • Global
From
RNA Therapy Clinical Trials Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2020-2030F - Product Image

RNA Therapy Clinical Trials Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2020-2030F

  • Report
  • 184 Pages
  • Global
From

About the RNA Therapy Market

RNA therapy is a form of gene therapy that uses RNA molecules to treat or prevent diseases. It is a type of genomics-based therapy that works by introducing genetic material into cells to modify their behavior. RNA therapy can be used to treat a variety of diseases, including cancer, neurological disorders, and infectious diseases. It has the potential to be used to treat genetic disorders, as well as to modify the expression of genes in order to improve the effectiveness of existing treatments. RNA therapy works by introducing genetic material into cells, which can then be used to modify the expression of genes. This can be done by introducing a gene that produces a therapeutic protein, or by introducing a gene that silences a gene that is causing a disease. RNA therapy can also be used to modify the expression of existing genes, which can be used to improve the effectiveness of existing treatments. RNA therapy is an emerging field of genomics-based therapy, and is being explored by a number of companies. Examples of companies in the RNA therapy market include Moderna, BioNTech, and Arcturus Therapeutics. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.